<DOC>
	<DOCNO>NCT02626065</DOCNO>
	<brief_summary>This open mono-centric prospective non-randomized study patient metastatic melanoma treat Anti-PD1 monoclonal antibody ( Nivolumab ) . The aim study identify immune cell modulation difference patient present complete , partial stable response patient non-response therapy order establish improve response rate strategy .</brief_summary>
	<brief_title>Immune Modulation Study Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Men woman age â‰¥ 18 year Patient metastatic unresectable melanoma AntiPD1 monoclonal antibody treatment indication Patient affiliate social security regime Signed Written Informed Consent . agree storage biological sample Women childbearing potential must mention summary product characteristic ( SPC ) use two effective method contraception treatment , men whose partner childbearing potential must use effective contraception treatment . For patient treat men woman , contraception continue four month follow discontinuation nivolumab . development haematological tumor treatment Patients require concomitant chronic treatment systemic corticosteroid immunosuppressive agent Patients autoimmune disease . Patient Occular melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Anti-PD1 monoclonal antibody</keyword>
	<keyword>Immune modulation</keyword>
	<keyword>BRAF</keyword>
</DOC>